Anika Therapeutics Inc (ANIK)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Anika Therapeutics Inc (ANIK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012294
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Anika Therapeutics Inc (Anika) is a medical technology company which develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products include viscosupplementation and regenerative orthopedics products, advanced wound care devices, anti-adhesion gels, viscoelastic ophthalmic products, dental bone grafting adjuncts and joint dysfunction management fluids for horses. Its products are made from hyaluronic acid (HA) based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Anika has research and manufacturing facilities in Bedford, Massachusetts. The company offers its products through distributors in the Americas, Europe, the Middle East, and Asia. Anika is headquartered in Massachusetts, the US.

Anika Therapeutics Inc (ANIK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Anika Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anika Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Anika Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anika Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Anika Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Anika Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Anika Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Anika Therapeutics Enters into Agreement with PendoPharm 11
Anika Therapeutics Enters into Research Agreement with University of Massachusetts Amherst 12
Nycomed Enters Into Distribution Agreement With Almirall, Anika, Bionorica, CSL And Helsinn 13
Anika Therapeutics Inc – Key Competitors 15
Anika Therapeutics Inc – Key Employees 16
Anika Therapeutics Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Strategy And Business Planning 18
May 23, 2017: Anika Celebrates 25th Anniversary and Inaugurates Newly Expanded and Consolidated Global Manufacturing Facility in Bedford, Massachusetts 18
Financial Announcements 19
Oct 25, 2017: Anika Reports Third Quarter 2017 Financial Results 19
Jul 26, 2017: Anika Reports Strong Second Quarter 2017 Financial Results 20
May 03, 2017: Anika Reports First Quarter 2017 Financial Results 21
Feb 15, 2017: Anika Reports Fourth Quarter and Full Year 2016 Financial Results 22
Feb 15, 2017: Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011 23
Oct 26, 2016: Anika Reports Third Quarter 2016 Financial Results 24
Jul 27, 2016: Anika Reports Second Quarter 2016 Financial Results 25
Apr 27, 2016: Anika Reports First Quarter 2016 Financial Results 26
Feb 24, 2016: Anika Therapeutics Delivers Strong Performance with Record Product Revenue for the Fourth Quarter and Full Year 2015 27
Corporate Communications 28
Oct 23, 2017: Anika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources Officer 28
Jul 27, 2017: Anika Announces Appointment of Joseph Darling as President 29
Apr 04, 2016: Anika Appoints New Chief Medical Officer and Chief Operations Officer 30
Product News 31
May 25, 2017: Anika Announces First Patient Enrolled in Supplemental Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Anika Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Anika Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anika Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Anika Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anika Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Anika Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Anika Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Anika Therapeutics Enters into Agreement with PendoPharm 11
Anika Therapeutics Enters into Research Agreement with University of Massachusetts Amherst 12
Nycomed Enters Into Distribution Agreement With Almirall, Anika, Bionorica, CSL And Helsinn 13
Anika Therapeutics Inc, Key Competitors 15
Anika Therapeutics Inc, Key Employees 16
Anika Therapeutics Inc, Subsidiaries 17

★海外企業調査レポート[Anika Therapeutics Inc (ANIK)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG, BAY 1905254, COM902 and TIGIT; and CGEN-XXXX/Myeloid and autoimmune diseases …
  • Cynosure Inc (CYNO):企業の財務・戦略的SWOT分析
    Summary Cynosure Inc (Cynosure), a subsidiary of Hologic Inc, is a developer, manufacturer and supplier of light-based aesthetic and medical treatment systems. Its products facilitate non-invasive body contouring, skin revitalization and scar reduction, cellulite reduction, hair removal, gynecologic …
  • CONSOL Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    CONSOL Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary CONSOL Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on …
  • NorgesGruppen ASA:企業の戦略的SWOT分析
    NorgesGruppen ASA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • K.P.R. Mill Ltd:企業の戦略・SWOT・財務分析
    K.P.R. Mill Ltd - Strategy, SWOT and Corporate Finance Report Summary K.P.R. Mill Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Suffolk Construction Company Inc:企業の戦略・SWOT・財務情報
    Suffolk Construction Company Inc - Strategy, SWOT and Corporate Finance Report Summary Suffolk Construction Company Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Indiana Resources Limited:企業の戦略・SWOT・財務分析
    Indiana Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Indiana Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Enable Midstream Partners LP (ENBL):石油・ガス:M&Aディール及び事業提携情報
    Summary Enable Midstream Partners, LP (Enable), a subsidiary of CenterPoint Energy Inc, owns, operates, and develops natural gas and crude oil infrastructure assets. It is a limited partnership among CenterPoint Energy, OGE Energy and ArcLight Capital Partners, LLC. The company offers crude oil and …
  • Vect-Horus SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Vect-Horus SAS (Vect-Horus) is a biotechnology company that designs and develops peptide-based vectors to facilitate the delivery of drugs or imaging agents into organs including the brain and tumors. The company combines molecules of interest to peptide-vectors that targets receptor mediate …
  • Exactech Inc (EXAC):企業の財務・戦略的SWOT分析
    Summary Exactech Inc (Exactech) is a medical device company that offers orthopedic implant devices and related surgical instruments. The company’s products comprise hip implants, shoulder implants, knee implants, extremity implants, biologics and spine, and other products. It also provides biologic …
  • Aevis Victoria SA (AEVS):製薬・医療:M&Aディール及び事業提携情報
    Summary Aevis Victoria SA (Aevis Victoria), a subsidiary of Medical Research, Services & Investments SA, is a diversified company that invests in healthcare, hospitality, telemedicine, life sciences and lifestyle. It owns and operates outpatient surgical centres, hospitals, medical network, and cent …
  • Ajinomoto Co., Inc.:企業の戦略・SWOT・財務情報
    Ajinomoto Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Ajinomoto Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • GATT Technologies BV:製品パイプライン分析
    Summary GATT Technologies BV (GATT Technologies) is a medical technology company, which develops synthetic surgical hemostat and sealant products that control severe bleeding. Its product pipeline includes GATT-Patch for controlling excessive bleeding; GATT-Tape for blocking intestinal anastomotic l …
  • EBN B.V.:石油・ガス:M&Aディール及び事業提携情報
    Summary EBN BV (EBN) is an independent oil and natural gas company that carries out exploration, production, storage and trading of oil and natural gas. The company participates in nearly all the exploration and production activities in the Netherlands through a public-private partnership model. It …
  • Proengin:企業の戦略・SWOT・財務情報
    Proengin - Strategy, SWOT and Corporate Finance Report Summary Proengin - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • MAN SE:企業の戦略・SWOT・財務情報
    MAN SE - Strategy, SWOT and Corporate Finance Report Summary MAN SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Hdfc Bank Ltd:企業の戦略・SWOT・財務分析
    Hdfc Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Hdfc Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • ENCE Energia Y Celulosa SA (ENC):企業の財務・戦略的SWOT分析
    ENCE Energia Y Celulosa SA (ENC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • BioLight Israeli Life Sciences Ltd (BOLT):医療機器:M&Aディール及び事業提携情報
    Summary BioLight Israeli Life Sciences Ltd (Bio-Light), formerly Bio Light Israeli Life Sciences Investments Ltd is an ophthalmic company that discovers, develops and commercializes products and product candidates for various ophthalmic conditions. The company invests in managing and commercializing …
  • Carlsberg AS (CARL B):企業の財務・戦略的SWOT分析
    Carlsberg AS (CARL B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆